The estimated Net Worth of David Kupfer is at least $595 mil dollars as of 1 December 2021. David Kupfer owns over 55,635 units of Minerva Neurosciences Inc stock worth over $436,687 and over the last 9 years he sold NERV stock worth over $48,959. In addition, he makes $109,197 as Independent Director at Minerva Neurosciences Inc.
David has made over 5 trades of the Minerva Neurosciences Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 55,635 units of NERV stock worth $48,959 on 1 December 2021.
The largest trade he's ever made was buying 181,488 units of Minerva Neurosciences Inc stock on 17 March 2016 worth over $999,999. On average, David trades about 32,283 units every 139 days since 2015. As of 1 December 2021 he still owns at least 163,553 units of Minerva Neurosciences Inc stock.
You can see the complete history of David Kupfer stock trades at the bottom of the page.
Dr. David J. Kupfer M.D. serves as Independent Director of the Company. Dr. Kupfer has served on our Board since he was elected by the Board in November 2015. Dr. Kupfer is Distinguished Professor Emeritus of Psychiatry at the University of Pittsburgh School of Medicine, where he chaired that department for 26 years. He also chaired the American Psychiatric Association Task Force for the development of the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders, or DSM-5, which defines the criteria for the diagnosis and classification of mental disorders. Dr. Kupfer received his M.D. from Yale University in 1965. Our Board believes that Dr. Kupfer’s extensive experience in the field of psychiatry qualifies him to serve on our Board.
As the Independent Director of Minerva Neurosciences Inc, the total compensation of David Kupfer at Minerva Neurosciences Inc is $109,197. There are 13 executives at Minerva Neurosciences Inc getting paid more, with Michael Davidson having the highest compensation of $2,842,430.
David Kupfer is 79, he's been the Independent Director of Minerva Neurosciences Inc since 2015. There are no older and 20 younger executives at Minerva Neurosciences Inc.
David's mailing address filed with the SEC is C/O MINERVA NEUROSCIENCES, INC.,, 1500 DISTRICT AVENUE, BURLINGTON, MA, 01803.
Over the last 10 years, insiders at Minerva Neurosciences Inc have traded over $49,043,620 worth of Minerva Neurosciences Inc stock and bought 8,182,692 units worth $47,876,311 . The most active insiders traders include & Johnson Johnson & Johnson..., Venture Associates Iii Ltd ... y Capital Iii Llc Care Capita.... On average, Minerva Neurosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $556,476. The most recent stock trade was executed by Remy Luthringer on 28 April 2023, trading 27,394 units of NERV stock currently worth $105,193.
minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its
Minerva Neurosciences Inc executives and other stock owners filed with the SEC include: